Language:

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Blood, 2020-12, Vol.136 (26), p.3033-3040 [Peer Reviewed Journal]

2020 American Society of Hematology ;2020 ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2020008150 ;PMID: 33367546

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
Author: Chari, Ajai ; Samur, Mehmet Kemal ; Martinez-Lopez, Joaquin ; Cook, Gordon ; Biran, Noa ; Yong, Kwee ; Hungria, Vania ; Engelhardt, Monika ; Gay, Francesca ; García Feria, Ana ; Oliva, Stefania ; Oostvogels, Rimke ; Gozzetti, Alessandro ; Rosenbaum, Cara ; Kumar, Shaji ; Stadtmauer, Edward A. ; Einsele, Hermann ; Beksac, Meral ; Weisel, Katja ; Anderson, Kenneth C. ; Mateos, María-Victoria ; Moreau, Philippe ; San-Miguel, Jesus ; Munshi, Nikhil C. ; Avet-Loiseau, Hervé
Subjects: Adult ; Aged ; Aged, 80 and over ; COVID-19 - complications ; Female ; Humans ; Internationality ; Lymphoid Neoplasia ; Male ; Middle Aged ; Multiple Myeloma - complications ; Multiple Myeloma - virology ; Multivariate Analysis ; Odds Ratio ; Risk Factors ; SARS-CoV-2 - physiology ; Societies, Medical
Is Part Of: Blood, 2020-12, Vol.136 (26), p.3033-3040
Description: The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19–infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during the COVID-19 pandemic. Analyses were performed for hospitalized MM patients. Among hospitalized patients, the median age was 69 years, and nearly all patients (96%) had MM. Approximately 36% were recently diagnosed (2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, International Staging System stage 3 (ISS3), high-risk disease, renal disease, suboptimal myeloma control (active or progressive disease), and 1 or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient- and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection. •High but variable mortality for hospitalized MM patients (27% to 57%).•Uncontrolled MM in the setting of COVID-19 infection was associated with an increased risk of death. [Display omitted]
Publisher: United States: Elsevier Inc
Language: English
Identifier: ISSN: 0006-4971
EISSN: 1528-0020
DOI: 10.1182/blood.2020008150
PMID: 33367546
Source: Freely Accessible Journals
MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

2020 American Society of Hematology ;2020 ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2020008150 ;PMID: 33367546

Searching Remote Databases, Please Wait